Search Results - "Inami, Nao"

Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer by Karayama, Masato, Inui, Naoki, Inoue, Yusuke, Yoshimura, Katsuhiro, Mori, Kazutaka, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Asada, Kazuhiro, Uto, Tomohiro, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Kusagaya, Hideki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Niwa, Mitsuru, Ito, Yasuhiro, Suda, Takafumi

“…Background Lipids have immunomodulatory functions and the potential to affect cancer immunity. Methods The associations of pretreatment serum cholesterol and…”
Get full text

Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study by Karayama, Masato, Inui, Naoki, Inoue, Yusuke, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Asada, Kazuhiro, Nishimoto, Koji, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Ikeda, Masaki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Funayama, Satoshi, Ichikawa, Shintaro, Goshima, Satoshi, Suda, Takafumi

“…Immune-related pneumonitis (irP) is one of the most important immune-related adverse events caused by immune checkpoint inhibitors (ICIs). After corticosteroid…”
Get full text

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study by Karayama, Masato, Inui, Naoki, Inoue, Yusuke, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Asada, Kazuhiro, Uto, Tomohiro, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Ikeda, Masaki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Funayama, Satoshi, Ichikawa, Shintaro, Goshima, Satoshi, Suda, Takafumi

“…BackgroundThere has been no prospective trial for treatment of immune-related pneumonitis (irP) occurred after immune checkpoint inhibitors (ICIs).MethodsIn…”
Get full text

Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer by Inoue, Yusuke, Yoshimura, Katsuhiro, Nishimoto, Koji, Inui, Naoki, Karayama, Masato, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Asada, Kazuhiro, Uto, Tomohiro, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Kusagaya, Hideki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Niwa, Mitsuru, Ito, Yasuhiro, Sugimura, Haruhiko, Suda, Takafumi

“…Robust predictors for response to anti-programmed death 1 and its ligand (PD-1/PD-L1) immunotherapy in non-small cell lung cancer (NSCLC) are not fully…”
Get full text

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial by Inui, Naoki, Suzuki, Takahito, Tanaka, Kazuki, Karayama, Masato, Inoue, Yusuke, Mori, Kazutaka, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Matsuura, Shun, Nishimoto, Koji, Matsui, Takashi, Asada, Kazuhiro, Hashimoto, Dai, Fujii, Masato, Niwa, Mitsuru, Uehara, Masahiro, Matsuda, Hiroyuki, Koda, Keigo, Ikeda, Masaki, Inami, Nao, Tamiya, Yutaro, Kato, Masato, Nakano, Hideki, Mino, Yasuaki, Enomoto, Noriyuki, Suda, Takafumi

“…We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT ) RA, and…”
Get full text

Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer by Inoue, Yusuke, Inui, Naoki, Karayama, Masato, Asada, Kazuhiro, Matsuura, Shun, Ikeda, Masaki, Uto, Tomohiro, Fujii, Masato, Hashimoto, Dai, Matsui, Takashi, Matsuda, Hiroyuki, Inami, Nao, Toyoshima, Mikio, Kaida, Yusuke, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Suda, Takafumi

“…Purpose Identifying patients at high risk of immune-related adverse events (irAEs) that impede the achievement of durable efficacy of programmed cell death 1…”
Get full text

Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma by Akiyama, Norimichi, Karayama, Masato, Inui, Naoki, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Inami, Nao, Matsuura, Shun, Kaida, Yusuke, Uto, Tomohiro, Matsui, Takashi, Asada, Kazuhiro, Matsuda, Hiroyuki, Fujii, Masato, Toyoshima, Mikio, Suda, Takafumi

“…Summary Background Optimal maintenance therapy for lung squamous cell carcinoma (SCC) has not been established. The aim of this study was to evaluate the…”
Get full text

Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study by Nishimoto, Koji, Karayama, Masato, Inui, Naoki, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Inami, Nao, Matsuura, Shun, Kaida, Yusuke, Matsui, Takashi, Asada, Kazuhiro, Matsuda, Hiroyuki, Fujii, Masato, Toyoshima, Mikio, Imokawa, Shiro, Suda, Takafumi

“…Switch maintenance therapy, using alternative agents that were not administered during induction chemotherapy, is a treatment option for advanced non-squamous…”
Get full text

Clinical Outcomes of Anti-programmed Death-1 Antibody–Related Pneumonitis in Patients with Non-Small Cell Lung Cancer by Koyauchi, Takafumi, Inui, Naoki, Karayama, Masato, Kitahara, Yoshihiro, Takuma, Sho, Amano, Yusuke, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Niwa, Mitsuru, Inami, Nao, Ito, Yasuhiro, Kusagaya, Hideki, Matsuura, Shun, Kaida, Yusuke, Uto, Tomohiro, Hashimoto, Dai, Matsui, Takashi, Asada, Kazuhiro, Matsuda, Hiroyuki, Fujii, Masato, Toyoshima, Mikio, Suda, Takafumi

“…Immune checkpoint inhibitors have provided a breakthrough in cancer therapy. Pneumonitis related to immune checkpoint inhibitors is a serious immune-related…”
Get full text

Inconsistency in the A-DROP system of the JRS guidelines for the management of community-acquired pneumonia and its outcome in adults by Tsuchiya, Tomoyoshi, Fujita, Akifumi, Ashizawa, Hiroki, Inami, Nao, Yoshitomi, Atsushi, Masuda, Masafumi, Suda, Takafumi, Chida, Kingo

“…We evaluated the consistency of the A-DROP system for community-acquired pneumonia (CAP) and its outcomes, and developed a new severity classification of…”
Get more information

Case of pulmonary aspergilloma in the apices of both lungs which was associated with welder's lung by Ashizawa, Hiroki, Fujita, Akifumi, Inami, Nao, Tsuchiya, Tomoyoshi, Yoshitomi, Atsushi, Masuda, Masafumi, Kageyama, Yoshihiko, Tsukamoto, Hiroshi, Suda, Takafumi, Chida, Kingo

“…A 48-year-old man, who had worked as a welder for 30 years, was admitted to our hospital with bloody sputum. His chest CT scan showed diffuse centrilobular…”
Get more information